Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, responded to a BMJ Study which provides new estimates of breast cancer risks associated with HRT.
Baroness Delyth Morgan, Chief Executive of Breast Cancer Now, said:
"While we’ve known for some time that HRT increases the risk of breast cancer, this study suggests that the risks associated with long-term use of HRT are lower than those previously reported.
"Further research is now needed, so that we can fully understand the differences in risks associated with various HRT treatments, and to understand how and why HRT increases women’s risk of developing breast cancer.
"For many women, HRT can be really effective in helping them to control debilitating menopausal symptoms such as hot flushes.
"For these women, generally it will be recommended that they take the lowest effective dose of HRT over the shortest possible time period, to minimise their risk of developing breast cancer as a result of taking HRT.
"What we do know is that taking HRT is a really personal decision for each individual; there is no ‘one size fits all’ approach.
"This is why, with information on HRT often being complex, it’s so vital that women discuss the benefits and risks of HRT with their GP, so that they are able to make an informed decision that will best meet their individual needs.
"In addition to speaking to their GP, anyone concerned about HRT and the associated risk of breast cancer call speak to our expert nurses, by calling our free Helpline on 0808 800 6000."